comparemela.com
Home
Live Updates
Innovent Announces First Participant Dosed in a Phase 3 Clin
Innovent Announces First Participant Dosed in a Phase 3 Clin
Innovent Announces First Participant Dosed in a Phase 3 Clinical Study (DREAMS-1) of Mazdutide (IBI362) in Chinese Patients with Type 2 Diabetes
/PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes...
Related Keywords
Taiwan ,
United States ,
Hong Kong ,
Suzhou ,
Jiangsu ,
China ,
Macau ,
Nanjing ,
Shandong ,
Chinese ,
Innovent Biologics ,
Adimab Incyte ,
Jiajun Zhao ,
Dalong Zhu ,
Eli Lilly ,
Company Lilly ,
Clinical Development At Innovent ,
Prnewswire Innovent Biologics Inc ,
Md Anderson Cancer Center ,
Incyte Corporation ,
Innovent Rd Code ,
Nanjing Drum Tower Hospital ,
Shandong Provincial Hospital ,
Lei Qian ,
Vice President ,
Clinical Development ,
Main Board ,
Stock Exchange ,
Hong Kong Limited ,
Cancer Center ,
Mainland China ,